Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Podcast for MM

HealthTree Podcast for Multiple Myeloma

×  

Follow This Show

Stay in the know about new episodes and updates.
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

On-Demand Episodes

AL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join HealthTree Podcast for Multiple Myeloma by HealthTree to hear... more

CAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma... more

Dr. Robert Z. Orlowski joins HealthTree Podcast for Multiple Myeloma to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting... more

Dr. Irene Ghobrial joins HealthTree Podcast for Multiple Myeloma to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to... more

The coronavirus continues to be a global concern for all citizens and especially for cancer patients. Where are we at now with our learning over the last seven months? Dr. Joshua Richter re-joins HealthTree Podcast for Multiple Myeloma... more

Venetoclax (Venclexta) is being studied in myeloma clinical trials and particular benefit has been seen in 11;14 myeloma patients. It is the first time a true precision medicine drug has been identified in myeloma. Which clinical trial... more

Dr. Ali is the primary investigator on a clinical trial to use a vaccine to extend remissions following successful myeloma treatment. The GVAX study is open for patients who are MRD positive but don't yet have a measurable m-protein. Dr.... more

Since HealthTree for Multiple Myeloma started our advocacy work in myeloma, the most common question we get is ?What supplements, diet or other alternative treatments will help my myeloma?? Whether it's yoga, supplements, massage... more

Myeloma specialists and myeloma patients alike want to know which treatment will work best before they are taken. Dr. Keith Stewart and colleagues from the Mayo Clinic Scottsdale have developed a new test using a "direct-to-drug"... more

Isatuxiab (Sarclisa) by Sanofi Genzyme is a new CD38-targeting monoclonal antibody that is now FDA approved to be combined with pomalidomide and dexamethasone. In the same drug class as daratumumab, isatuximab is different... more
Show Extras

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled